University of Zurich

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

262

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

3 drugs in development

Phase 32

Phase 11

Preclinical1

By Therapeutic Area

top 2

Infectious Disease

250%

Cardiovascular

125%

R&D Momentum

75/100

Pipeline Velocity

45/100

Trial Completion Rate

83/100

Pipeline Concentration

38/100

Pipeline Freshness

30/100

Strategic Signals

↗Active in Infectious Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Nov 3, 2026

Completed

A Phase I Clinical Study on Feasibility and Toxicity of LINAC-based Flash Radiotherapy for Palliative Treatment of Skin Lesions of Malignant Melanomas

Oct 29, 2026

Completed

Tumor Heterogeneity of Renal Tumors Assessed by Multiparametric MRI With Direct Radiological-histopathological Correlation: an Explorative Study

Oct 27, 2026

Enrolling by invitation

Retrospective Data Analysis of Neurophysiological Data for Intraoperative or Epilepsy Monitoring

Oct 24, 2026

Enrolling by invitation

Patient Registry of the Neurosurgery Department.

Earlier

Oct 22, 2026TrialLong Term Outcome After Use of Vacuum-induced Tamponade for Postpartum Hemorrhage at a Single Tertiary Center

Oct 9, 2026TrialPersonalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck

Sep 26, 2026TrialEuropean Multicentre Study of Human SCI

Sep 26, 2026TrialMolecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling: the BIOCARDIUM-HF Study

3 more events

Sep 22, 2026TrialPharmacoscopy for Patients With Refractory Primary Brain Tumors

Sep 22, 2026TrialAdvanced Neurofeedback for Tinnitus Applying Representational EEG Signatures

Sep 22, 2026TrialSafusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

PycnogenolPreclinical

Infectious Disease

COVID-19

PycnogenolPhase 3

Tuberculosis

NivaquinePhase 1

Unknown / Other

Menstrual Pain

BryophyllumPhase 3

Regulatory

Regulatory Timeline

201316 events

FDASep 7

Oxygen — OXYGEN, USP

Application NDA206023

FDASep 3

Oxygen — NITROUS OXIDE, USP

Application NDA206009

FDAAug 27

Oxygen — OXYGEN, USP

Application NDA205986

FDAAug 2

Oxygen — OXYGEN, USP

Application NDA205889

FDAJul 23

Oxygen — OXYGEN, USP

Application NDA205862

FDAJul 23

Oxygen — OXYGEN, USP

Application NDA205865

FDAJul 21

Oxygen — OXYGEN, USP

Application NDA205849

FDAJul 20

Oxygen — HELIUM, USP

Application NDA205843

FDAJul 16

Oxygen — OXYGEN, USP

Application NDA205840

FDAJul 14

Oxygen — OXYGEN, USP

Application NDA205820

FDAJul 5

Oxygen — OXYGEN, USP

Application NDA205767

FDAJul 5

Oxygen — OXYGEN, USP

Application NDA205818

FDAJul 5

Oxygen — OXYGEN, USP

Application NDA205817

FDAJul 5

Oxygen — CARBON DIOXIDE, USP

Application NDA205764

FDAJun 23

Oxygen — OXYGEN, USP

Application NDA205737

FDAJun 16

Oxygen — OXYGEN, USP

Application NDA205712

20171 event

FDADec 17

Oxygen — MEDICAL AIR, USP

Application NDA211270

20182 events

FDASep 10

Oxygen — OXYGEN, USP

Application NDA211739

FDAAug 24

Oxygen — OXYGEN, USP

Application NDA212314

20221 event

FDAJun 10

Oxygen — OXYGEN, USP

Application NDA217500

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)